These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9023657)

  • 1. Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones.
    Moreau NJ; Houot S; Joly-Guillou ML; Bergogne-Bérézin E
    J Antimicrob Chemother; 1996 Dec; 38(6):1079-83. PubMed ID: 9023657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to fluoroquinolones in Escherichia coli isolated from poultry.
    Bazile-Pham-Khac S; Truong QC; Lafont JP; Gutmann L; Zhou XY; Osman M; Moreau NJ
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1504-7. PubMed ID: 8726027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.
    Joly-Guillou ML; Bergogne-Bérézin E
    J Antimicrob Chemother; 1992 Apr; 29(4):466-8. PubMed ID: 1318878
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
    Denis A; Moreau NJ
    J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.
    Nakanishi N; Yoshida S; Wakebe H; Inoue M; Yamaguchi T; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2562-7. PubMed ID: 1667255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
    Gensberg K; Jin YF; Piddock LJ
    FEMS Microbiol Lett; 1995 Oct; 132(1-2):57-60. PubMed ID: 7590165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Compared antibacterial activity of a new fluoroquinolone, sparfloxacin (AT 4140, RP 64206) and four other fluoroquinolones against 332 strains of enteropathogen bacteria].
    Le Noc P; Croizé J; Le Noc D
    Pathol Biol (Paris); 1993 Apr; 41(4):294-301. PubMed ID: 8233625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.
    Nakanishi N; Yoshida S; Wakebe H; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1053-9. PubMed ID: 1656852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD; Martin BA
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.
    Bazile S; Moreau N; Bouzard D; Essiz M
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2622-7. PubMed ID: 1336340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.
    Cambau E; Perani E; Dib C; Petinon C; Trias J; Jarlier V
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2248-52. PubMed ID: 8619577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.
    Zhanel GG; Karlowsky JA; Saunders MH; Davidson RJ; Hoban DJ; Hancock RE; McLean I; Nicolle LE
    Antimicrob Agents Chemother; 1995 Feb; 39(2):489-95. PubMed ID: 7726519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance mechanism of Acinetobacter spp. strains resistant to DW-116, a new quinolone.
    Choi KH; Baek MC; Kim BK; Choi EC
    Arch Pharm Res; 1998 Jun; 21(3):310-4. PubMed ID: 9875449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.